La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

T2 Biosystems Gestion

Gestion contrôle des critères 4/4

Le PDG T2 Biosystems' est John Sperzel, nommé en Jan2020, a un mandat de 4.58 ans. La rémunération annuelle totale est $ 865.50K, composée du salaire de 66.4% et des bonus 33.6%, y compris les actions et options de la société. détient directement 0.002% des actions de la société, d'une valeur de $ 1.48K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 5.6 ans et 7.5 ans.

Informations clés

John Sperzel

Directeur général

US$865.5k

Rémunération totale

Pourcentage du salaire du PDG	66.4%
Durée du mandat du directeur général	4.7yrs
Propriété du PDG	0.002%
Durée moyenne d'occupation des postes de direction	5.7yrs
Durée moyenne du mandat des membres du conseil d'administration	7.5yrs

Mises à jour récentes de la gestion

Recent updates

T2 Biosystems stock rises ~17% after hours on Baltic region distribution agreement

Sep 22

T2 Biosystems' Survival Riddle

Aug 26

T2 Biosystems Q2 2022 Earnings Preview

Aug 12

T2 Biosystems drops 4% on Q2 guidance and 2022 outlook

Jul 06

Analyse de la rémunération des PDG

Comment la rémunération de John Sperzel a-t-elle évolué par rapport aux bénéfices de T2 Biosystems?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	-US$48m
Mar 31 2024	n/a	n/a	-US$46m
Dec 31 2023	US$866k	US$575k	-US$50m
Sep 30 2023	n/a	n/a	-US$50m
Jun 30 2023	n/a	n/a	-US$52m
Mar 31 2023	n/a	n/a	-US$64m
Dec 31 2022	US$2m	US$575k	-US$62m
Sep 30 2022	n/a	n/a	-US$64m
Jun 30 2022	n/a	n/a	-US$61m
Mar 31 2022	n/a	n/a	-US$55m
Dec 31 2021	US$4m	US$563k	-US$49m
Sep 30 2021	n/a	n/a	-US$47m
Jun 30 2021	n/a	n/a	-US$44m
Mar 31 2021	n/a	n/a	-US$43m
Dec 31 2020	US$3m	US$491k	-US$47m

Rémunération vs marché: La rémunération totale de John ($USD 865.50K ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 667.63K ).

Rémunération et revenus: La rémunération de John a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

John Sperzel (61 yo)

4.7yrs

Titularisation

US$865,500

Compensation

Mr. John J. Sperzel, III, B.Sc., serves as Chief Executive Officer and Director of T2 Biosystems, Inc. since January 8, 2020 and has been its Chairman since July 23, 2021 and serves as President. Mr. Sperz...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
John Sperzel	President	4.7yrs	US$865.50k	0.0023% $ 800.6
John Sprague	Chief Financial Officer	6.7yrs	US$581.00k	0.00081% $ 283.2
Michael Gibbs	Senior VP	8.7yrs	US$622.60k	0.00077% $ 269.2
Kelley Morgan	Chief People Officer	10.5yrs	pas de données	pas de données
Brett Giffin	Chief Commercial Officer	2.8yrs	pas de données	0.00044% $ 153.8
Roger Smith	Senior Vice President of Science Research & Development	2.5yrs	pas de données	pas de données

5.7yrs

Durée moyenne de l'emploi

60yo

Âge moyen

Gestion expérimentée: L'équipe de direction de TTOO est chevronnée et expérimentée (ancienneté moyenne 5.6 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
John Sperzel	President	4.7yrs	US$865.50k	0.0023% $ 800.6
Robin Toft	Independent Director	4.3yrs	US$60.00k	0.00033% $ 115.4
Seymour E. Liebman	Independent Director	8yrs	US$40.00k	0.00049% $ 171.3
John Cumming	Lead Independent Director	10.2yrs	US$96.00k	0.00030% $ 104.9
David Elsbree	Independent Director	10.2yrs	US$60.00k	0.00014% $ 48.9
Eric Rosenberg	Member of Clinical Advisory Board	13.3yrs	pas de données	pas de données
Louis Rice	Member of Clinical Advisory Board	13.3yrs	pas de données	pas de données
Ninfa Saunders	Independent Director	4.3yrs	US$50.00k	0.00042% $ 146.8
Peter Pappas	Member of Clinical Advisory Board	13.3yrs	pas de données	pas de données
Michael Pfaller	Member of Clinical Advisory Board	7.1yrs	US$1.10m	pas de données
Laura Adams	Independent Director	2.9yrs	US$40.00k	0.00021% $ 73.4
Sean Zhang	Member of Scientific Advisory Board	2.4yrs	pas de données	pas de données

7.5yrs

Durée moyenne de l'emploi

70yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de TTOO sont considérés comme expérimentés (ancienneté moyenne 7.5 ans).

T2 Biosystems Gestion

Gestion contrôle des critères 4/4

Informations clés

Mises à jour récentes de la gestion

T2 Biosystems, Inc. Announces the Resignation of Thierry Bernard as Class II Director and All Committees of the Board of Directors

Insufficient new directors

T2 Biosystems, Inc., Annual General Meeting, Sep 12, 2023

High number of new directors

T2 Biosystems, Inc. Announces Resignation of Alec Barclay as Chief Operations Officer, Effective November 30, 2022

T2 Biosystems, Inc., Annual General Meeting, Oct 11, 2022

Recent updates

T2 Biosystems, Inc. Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients

T2 Biosystems, Inc. to Report Q2, 2024 Results on Jul 29, 2024

T2 Biosystems, Inc. has filed a Follow-on Equity Offering in the amount of $14.658742 million.

T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements

T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements

T2 Biosystems, Inc. announced that it expects to receive $8.000002 million in funding

T2 Biosystems, Inc. announced that it expects to receive $8.000002 million in funding

T2 Biosystems, Inc. has withdrawn its Follow-on Equity Offering.

T2 Biosystems, Inc. to Report Q1, 2024 Results on May 06, 2024

T2 Biosystems, Inc. has filed a Follow-on Equity Offering.

T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates

T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement

T2 Biosystems Announces Agreement with CRG for Conversion of Term Loan into Equity to Regain Compliance

T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria Panel

T2 Biosystems, Inc. to Report Q4, 2023 Results on Feb 15, 2024

T2 Biosystems Announces Participation in NIH-Funded Antibacterial Resistance Leadership Group (Arlg) Pilot Study for Pneumonia Patients

T2 Biosystems, Inc. Announces the Resignation of Thierry Bernard as Class II Director and All Committees of the Board of Directors

The Nasdaq Listing Qualifications Staff Issues Delist Determination to T2 Biosystems

The Nasdaq Listing Qualifications Staff Issues Delist Determination to T2 Biosystems

T2 Biosystems, Inc. announced delayed 10-Q filing

Insufficient new directors

T2 Biosystems, Inc. Highlights New Clinical Data Presented At IDWeek 2023 Conference

Consensus revenue estimates decrease by 21%, EPS upgraded

T2 Biosystems Provides Nasdaq Compliance Update

T2 Biosystems, Inc. to Report Q3, 2023 Results on Oct 12, 2023

T2 Biosystems Receives FDA 510(k) Clearance for the T2Biothreat Panel

Price target increased by 58% to US$0.15

T2 Biosystems, Inc. Updates Revenue Guidance for the Year 2023

T2 Biosystems Regains Compliance with Nasdaq’s Market Value of Listed Securities Requirement

T2 Biosystems Receives Extension through November 20, 2023 to Comply with Nasdaq's Minimum Bid Price and Market Value of Listed Securities Requirements

T2 Biosystems, Inc., Annual General Meeting, Sep 12, 2023

T2 Biosystems, Inc. to Report Q2, 2023 Results on Aug 07, 2023

T2 Biosystems, Inc. Receives FDA Breakthrough Device Designation for Candida Auris Diagnostic Test

T2 Biosystems, Inc. Provides Revenue Guidance for the Year 2023

T2 Biosystems, Inc. announced that it has received $0.1 million in funding from CR Group L.P.

T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for Candida Auris Diagnostic Test

T2 Biosystems Receives Letter from Nasdaq Regarding its Shares Failure to Comply with the Market Value of Listed Securities Required for Continued Listing on The Nasdaq Capital Market

T2 Biosystems, Inc. announced delayed 10-Q filing

Insufficient Growth At T2 Biosystems, Inc. (NASDAQ:TTOO) Hampers Share Price

Full year 2022 earnings: EPS misses analyst expectations

Consensus revenue estimates decrease by 50%, EPS upgraded

T2 Biosystems, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

T2 Biosystems, Inc. has completed a Follow-on Equity Offering.

T2 Biosystems, Inc. Announces Positive Results Upon Completion of U.S. Clinical Evaluation for the T2Biothreat Panel

T2 Biosystems Inc. Advances to the Phase 2 in HHS and the Steven and Alexandra Cohen Foundation's LymeX Diagnostics Prize

Consensus EPS estimates fall by 15%

Price target decreased to US$1.85

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new directors

T2 Biosystems, Inc. Announces Resignation of Alec Barclay as Chief Operations Officer, Effective November 30, 2022

T2 Biosystems Regains Compliance with Nasdaq’s Minimum Bid Price Rule

T2 Biosystems, Inc. to Report Q3, 2022 Results on Nov 10, 2022

T2 Biosystems, Inc. Initiates Studies to Add Acinetobacter Baumannii to the FDA-Cleared T2Bacteria Panel

T2 Biosystems, Inc. Announces Plan to Commercialize A Diagnostic Test for Early Lyme Disease

T2 Biosystems to develop, commercialize diagnostic test for early Lyme disease

T2 Biosystems, Inc. Updates Revenue Outlook for the Full Year of 2022

T2 Biosystems, Inc. Announces BARDA Exercise of Contract Option 3 Valued at $3.7 Million

T2 Biosystems announces BARDA exercise of contract option 3 valued at $3.7M

T2 Biosystems stock rises ~17% after hours on Baltic region distribution agreement

T2 Biosystems' Survival Riddle

T2 Biosystems, Inc., Annual General Meeting, Oct 11, 2022

T2 Biosystems, Inc. announced delayed 10-Q filing

T2 Biosystems Q2 2022 Earnings Preview

T2 Biosystems, Inc to Explore Potential to Develop Rapid Molecular Diagnostic Test for Monkeypox Virus

T2 Biosystems, Inc. to Report Q2, 2022 Results on Aug 15, 2022

T2 Biosystems Receives Non-Compliance Notice from Nasdaq

T2 Biosystems, Inc. Receives Food and Drug Administration Breakthrough Device Designation for the T2Lyme Panel

Consensus forecasts updated

T2 Biosystems, Inc. Provides Preliminary Unaudited Revenue Guidance for the Quarter Ended June 30, 2022 and Provides Revenue Guidance for the Full Year 2022